v
Weekly Readout
Oct 9, 2026
•
24 min read
Weekly Readout #25: Week ending October 9, 2026
Oct 7, 2026
19 min read
Breakthroughs from Europe's largest dermatological conference
Acquisitions
Oct 5, 2026
15 min read
How four professors teamed up with a serial entrepreneur to teach an old drug new tricks
Oct 2, 2026
25 min read
Breakthroughs & debates from Europe's largest diabetes conference
Sep 25, 2026
23 min read
Weekly Readout #24: Week ending September 25, 2026
Sep 21, 2026
13 min read
Nuclear fusion between two radiopharmaceutical powerhouses
Sep 18, 2026
11 min read
Weekly Readout #23: Week ending September 18, 2026
Sep 16, 2026
22 min read
Breakthroughs from the world’s largest lung cancer conference
Sep 11, 2026
20 min read
Weekly Readout #22: Week ending September 11, 2026
Sep 4, 2026
17 min read
Weekly Readout #21: Week ending September 4, 2026
Sep 1, 2026
Breakthroughs and debates from Europe's largest cardiology conference
Aug 31, 2026
9 min read
Laying traps for antibody rebels
Frontiers in Medicine
Aug 29, 2026
26 min read
How a 75-year collaboration between tech & biotech birthed the precision oncology revolution
Aug 28, 2026
Weekly Readout #20: Week ending August 28, 2026
Aug 21, 2026
Weekly Readout #19: Week ending August 20, 2026
Aug 18, 2026
Rare disease maven bets on a next generation bone-forming medicine
Aug 14, 2026
Weekly Readout #18: Week ending August 14, 2026
Aug 10, 2026
How David Goldstein's precision neuroscience thesis hit escape velocity
Aug 8, 2026
Exploring the Pax Pharmaceutica that never arrived
Aug 7, 2026
Weekly Readout #17: Week ending August 7, 2026
Medical History
Aug 1, 2026
How Pharmasset teamed up with Gilead and bested big pharma in the race for a cure
Jul 31, 2026
12 min read
Weekly Readout #16: Week ending July 31, 2026
Jul 27, 2026
10 min read
How Paul Wagner's pivot from microbiome medicines to CD122 for celiac and vitiligo paid off
Jul 24, 2026
Weekly Readout #15: Week ending July 24, 2026
Jul 18, 2026
How Schering-Plough, Roche, Merck, Vertex, and Janssen turned the tide from a public health epidemic to an 80% cure rate